Back to full portfolio

Billion To One

Molecular counting platform to help quantify nearly undetectable DNA changes, unlocking improvements to non-invasive prenatal screening and liquid biopsy.
WEBSITE
Founder(s)
Oguzhan Atay, PhD and David Tsao, PhD
SECTOR(S)
Healthcare
Investment Stage
Growth
Status
IPO/Public
Billion To OnePlay Icon

More about Billion To One

Perspectives

Investing in BillionToOne – Amplifying the power of molecular diagnostics

Read more

Investing in BillionToOne – Amplifying the power of molecular diagnostics

Read more
Perspectives

BillionToOne Announces Green Journal Publication that Underscores the Role of cell-free DNA NIPT for Fetal Red Blood Cell Antigen Genotyping

Read more

BillionToOne Announces Green Journal Publication that Underscores the Role of cell-free DNA NIPT for Fetal Red Blood Cell Antigen Genotyping

Read more
Perspectives

BillionToOne Celebrates Major Milestone: 1 Million UNITY Tests

Read more

BillionToOne Celebrates Major Milestone: 1 Million UNITY Tests

Read more
Perspectives

MITIGATING RHOGAM(R) SHORTAGE WITH UNITY FETAL RhD™ NON-INVASIVE PRENATAL TEST

Read more
Billion to One

MITIGATING RHOGAM(R) SHORTAGE WITH UNITY FETAL RhD™ NON-INVASIVE PRENATAL TEST

Read more
Perspectives

BillionToOne Announces Medicare Coverage for Northstar Select

Read more
PR Newswire

BillionToOne Announces Medicare Coverage for Northstar Select

Read more